Wearable Versus Office Blood Pressure Monitoring in Hemodialysis Patients
Compares wearable and office blood pressure guidance for hypertension in adults on hemodialysis.
Key facts
- Who runs it
- Gangnam Severance Hospital
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Wearable Ambulatory Vs. Office BP in Hemodialysis
- Status
- Not yet recruiting
- People taking part
- 280 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 30 Oct 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CART BP Pro-guided blood pressure management
- Conventional office blood pressure-guided management
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults on maintenance hemodialysis who have high blood pressure or take blood pressure medicine. It compares two ways of guiding blood pressure care.
- Age
- 19 years or older
- Sex
- All sexes can join
- Disease stage
- Kidney failure treated with hemodialysis three times per week for at least 3 months
- Earlier treatment
- On maintenance hemodialysis for at least 3 months
- Biomarker or test result
- Blood pressure before dialysis of ≥140/90 mmHg measured in the dialysis clinic before enrollment, or taking at least one blood pressure medicine
Main reasons for not taking part
- Implanted cardiac pacemaker
- Uncontrolled irregular heartbeat, such as persistent atrial fibrillation, that prevents pulse wave measurement
- Cannot wear the CART BP Pro device, for example because of finger deformity
- Life expectancy of less than 6 months
This trial only enrols participants on dialysis. The registry sentence this rests on: Patients receiving hemodialysis three times per week.
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adults aged 19 years or older
- Patients receiving hemodialysis three times per week
- On maintenance hemodialysis for at least 3 months
- Patients with a predialysis blood pressure (BP) of ≥140/90 mmHg measured in the dialysis clinic before study enrollment, or those taking at least one antihypertensive medication
- Individuals who provided informed consent to participate in the study
Who cannot take part
- Presence of an implanted cardiac pacemaker
- Patients in whom pulse wave measurement is not feasible due to uncontrolled arrhythmias (e.g., persistent atrial fibrillation)
- Inability to wear the CART BP Pro device (e.g., due to finger deformity)
- Life expectancy of less than 6 months
Where in South Korea
- Gangnam Severance HospitalSeoul, South KoreaContact: Jong Hyun Jhee, MD, PhDNot yet recruiting
About the trial
What the trial wants to find out
Hypertension is highly prevalent among patients receiving maintenance hemodialysis and is associated with increased cardiovascular morbidity and mortality. Accurate blood pressure assessment is essential for optimizing dry weight and antihypertensive therapy, but conventional office blood pressure measurements may not adequately capture the dynamic blood pressure variations that occur throughout the hemodialysis cycle, including the pre-, intra-, post-, and interdialytic periods. Wearable cuffless blood pressure monitoring may provide more comprehensive blood pressure data and facilitate individualized blood pressure management.
Read full original descriptionShow less
The WAVE-HD trial is a prospective, multicenter, single-blind, randomized controlled study designed to compare wearable blood pressure-guided hypertension management using the CART BP Pro device with conventional office blood pressure-guided management in adult patients receiving maintenance hemodialysis. Participants will be randomized in a 1:1 ratio to either the wearable blood pressure-guided management group or the office blood pressure-guided management group. Dry weight and antihypertensive medications will be adjusted according to the assigned blood pressure monitoring strategy. The primary objective of the study is to determine whether wearable blood pressure-guided management increases the proportion of patients achieving target blood pressure compared with conventional office blood pressure-guided management. Secondary outcomes include changes in blood pressure, blood pressure variability, dry weight, antihypertensive medication use, and safety.
The 2 groups in the trial
- Wearable blood pressure-guided managementTreatment being tested
Participants will undergo wearable blood pressure monitoring using the CART BP Pro device. Dry weight and antihypertensive medications will be adjusted according to wearable blood pressure measurements throughout the study.
Treatment: CART BP Pro-guided blood pressure management
- Conventional office blood pressure-guided managementExisting treatment, for comparison
Participants will undergo wearable blood pressure monitoring using the CART BP Pro device. However, dry weight and antihypertensive medications will be adjusted according to conventional office blood pressure measurements. Wearable blood pressure data will not be used for treatment decisions.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Wearable Ambulatory Versus Office Blood Pressure-Guided Hypertension Management in Hemodialysis Patients: A Multicenter, Single-Blind, Randomized Controlled Trial
- Plain-language title
- Wearable Versus Office Blood Pressure Monitoring in Hemodialysis PatientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 9 September 2026